Waters Corporation Announces Proposed Transaction with BD's Biosciences and Diagnostics Solutions

Details

The deal, valued at approximately $17.5 billion, aims to create a life science and diagnostics leader. The combined company is expected to have pro forma 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion. The transaction is anticipated to be accretive to adjusted EPS in the first year and create annualized EBITDA synergies of approximately $345 million by 2030. The deal has been approved by the Boards of Directors of both companies and is subject to regulatory approvals, Waters shareholder approval, and other customary closing conditions.

Items reported

Exhibits (2)

About Waters Corporation

Waters Corporation is a leading entity in the field of analytical instruments and software. It primarily focuses on providing laboratory solutions for a variety of sectors, including pharmaceuticals, healthcare, food and beverage, and chemical analysis. The company's offerings include high-performance liquid chromatography, mass spectrometry systems, and various supporting technologies used for advanced research in life sciences. Waters Corporation is pivotal in enhancing laboratory productivity, offering cutting-edge research tools that assist in drug development, quality control, and environmental testing. Operating globally, it serves a wide array of clients, including academic institutions, government agencies, and private industry players. With its commitment to innovation and precision, Waters Corporation plays a crucial role in advancing scientific and technological progress in multiple critical industries worldwide.